Axogen, INC Form 4 insider transactions

Director Paul Thomas reports acquiring shares and stock options in Axogen, Inc. as part of an annual equity grant.

Alan M. Levine, a director of Axogen, Inc., reported the acquisition of common stock and stock options related to his service on the board.

Director Guido J. Neels reports acquisition of common stock and stock options in Axogen, Inc. as part of an annual equity grant.

Director Joseph A. Tyndall reports acquisition of Axogen common stock and stock options as part of an annual equity grant.

Director Kathy Weiler reports acquisition of Axogen shares and stock options as part of annual equity grant.

Director Gregory Freitag reports accelerated vesting of restricted stock units resulting in changes in beneficial ownership of Axogen, Inc. shares.

Axogen's CEO, Karen Zaderej, reported the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Erick Wayne DeVinney, Chief Innovation Officer of Axogen, Inc., reports the vesting and sale of restricted stock units to cover tax obligations.

Angelo Scopelianos, Chief R&D Officer of Axogen, Inc., reports the vesting and sale of restricted stock units to cover tax obligations.

Michael Patrick Donovan, VP of Operations at Axogen, Inc., reports the vesting and sale of restricted stock units to cover tax obligations.

Michael Patrick Donovan, VP of Operations at Axogen, Inc., sold 36,310 shares of common stock at an average price of $8.81 on March 7, 2024.

Gregory Freitag, a director at Axogen, Inc., sold 25,000 shares of common stock at an average price of $9 per share on March 7, 2024.

Erick Wayne DeVinney, Chief Innovation Officer of Axogen, Inc., reported acquiring 50,000 shares of common stock on March 1, 2024.